<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78999">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01984346</url>
  </required_header>
  <id_info>
    <org_study_id>VAL-1200</org_study_id>
    <secondary_id>IDE Number G130084</secondary_id>
    <nct_id>NCT01984346</nct_id>
  </id_info>
  <brief_title>CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)</brief_title>
  <acronym>CONVERGE</acronym>
  <official_title>Convergence Of Epicardial And Endocardial Radiofrequency (RF) Ablation For The Treatment Of Symptomatic Persistent AF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>nContact Surgical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>nContact Surgical Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open label, randomized pivotal study evaluating the safety and
      efficacy of the EPi-Sense-AF Guided Coagulation System for the treatment of persistent AF
      patients, refractory or intolerant to at least one Class I and/or III Anti Arrhythmic Drug
      (AAD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AF/AT/Atrial Flutter(AFL) free absent class I and III AADs except for a previously failed or intolerant class I or III AAD with no increase in dosage.</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy endpoint is success or failure to be AF/AT/AFL free absent class I and III AADs except for a previously failed or intolerant class I or III AAD with no increase in dosage following the 3 month blanking period through the 12 months post procedure follow-up visit.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">153</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Convergent Procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined Epicardial / Endocardial Ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standalone Endocardial Catheter Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endocardial Catheter Ablation only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Convergent Procedure EPi-Sense-AF Guided Coagulation System</intervention_name>
    <description>Combined Epicardial Endocardial Ablation</description>
    <arm_group_label>Convergent Procedure</arm_group_label>
    <other_name>EPi-Sense-AF Guided Coagulation System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endocardial Catheter Ablation</intervention_name>
    <description>Endocardial Catheter Ablation only</description>
    <arm_group_label>Standalone Endocardial Catheter Ablation</arm_group_label>
    <other_name>Irrigated Endocardial Catheters</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years; &lt; 80 years

          -  Left atrium &lt; 6.0 cm

          -  History of AF for â‰¤ 10 years

          -  Refractory or intolerant to one AAD (class I and/or III)

          -  Documentation of persistent AF

          -  Provided written informed consent

        Exclusion Criteria:

          -  Patients requiring concomitant surgery

          -  Left ventricular ejection fraction &lt; 40%

          -  Pregnant or planning to become pregnant during study

          -  Co-morbid medical conditions that limit one year life expectancy

          -  Previous cardiac surgery

          -  History of pericarditis

          -  Previous cerebrovascular accident (CVA), excluding fully resolved transient Ischemic
             attack (TIA)

          -  Patients who have active infection or sepsis

          -  Patients with esophageal ulcers strictures and varices

          -  Patients with renal dysfunction who are not on dialysis

          -  Patients who are contraindicated for anticoagulants

          -  Patients who are being treated for ventricular arrhythmias

          -  Patients who have had a previous left atrial catheter ablation for AF

          -  Patients with existing Permanent Pacemakers (PPMs) and Implantable
             Cardioverter-Defibrillator (ICDs)

          -  Current participation in another clinical investigation of a medical device or a
             drug, or recent participation in such a study within 30 days prior to study
             enrollment

          -  Not competent to legally represent him or herself
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jagruti Vyas, BS</last_name>
    <phone>919-655-1354</phone>
    <email>jvyas@ncontactinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James G Whayne, MS</last_name>
    <phone>919-655-1561</phone>
    <email>jwhayne@ncontactinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Vincent Medical Group Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Simpkiss</last_name>
      <phone>317-583-6115</phone>
      <email>sara.simpkiss@stvincent.org</email>
    </contact>
    <contact_backup>
      <last_name>Andy Scroggs</last_name>
      <phone>317-338-9380</phone>
      <email>rascrogg@stvincent.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Olson, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Walts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Foundation of Louisiana</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Toler, RN, BSN</last_name>
      <phone>225-765-7733</phone>
      <email>btoler@crfla.org</email>
    </contact>
    <contact_backup>
      <last_name>Julie Young, LPN</last_name>
      <phone>225-765-7660</phone>
      <email>jyoung@crfla.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth Civello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cary Research Group, LLC/Wake Medical Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanee Tomasulo, RN BSN</last_name>
      <phone>919-622-7301</phone>
      <email>mtomasulo@wakemed.org</email>
    </contact>
    <investigator>
      <last_name>Pavlo Netrebko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bryon Boulton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny-Singer Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Snyder, RN BSN CCRC</last_name>
      <phone>412-359-3802</phone>
      <email>csnyder1@wpahs.org</email>
    </contact>
    <investigator>
      <last_name>Amit Thosani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Heart PLLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Hatch, CRC</last_name>
      <phone>512-421-3860</phone>
      <email>janet.hatch@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>David Tschopp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cardiovascular Specialists</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Adams, BS</last_name>
      <phone>804-521-5828</phone>
      <email>aadams@vacardio.com</email>
    </contact>
    <contact_backup>
      <last_name>Laura Puckett, RN</last_name>
      <phone>804-521-5829</phone>
      <email>lpuckett@vacardio.com</email>
    </contact_backup>
    <investigator>
      <last_name>John Onufer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>November 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Convergent Procedure</keyword>
  <keyword>Combined Epicardial/ Endocardial Ablation</keyword>
  <keyword>Hybrid Procedure</keyword>
  <keyword>Radiofrequency Ablation</keyword>
  <keyword>Arrhythmia</keyword>
  <keyword>RF Ablation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
